Henry Ruiz, MD
Urology · Edinburg, TXNPI 1245236348
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), speaking fees and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 60.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $6,783 and has fallen 85.7% since, to $972 in 2025.
Across 232 payments — averaging $50.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- Medtronic$3K
- Astellas Pharma US Inc$296
- Next Science LLC$270
- Sumitomo Pharma America, Inc.$223
- Bluewind Medical$163
- plus $966 from 16 others
Across 46 payments — averaging $3660.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$97K
- Bluewind Medical$62K
- Uromedica, Incorporated$9K
What the payments were for
- Consulting fees$1351%
- Speaking & faculty fees$5,40046%
- Food & beverage$5,99851%
- Education$1731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $7,028 |
| Medtronic(2 entities) | 147 | $2,759 |
| Astellas Pharma US Inc | 14 | $296 |
| Next Science LLC | 2 | $270 |
| Sumitomo Pharma America, Inc. | 7 | $223 |
| Bluewind Medical | 3 | $163 |
| Urogen Pharma, Inc. | 3 | $150 |
| Calyxo, Inc. | 1 | $128 |
| AbbVie | 7 | $127 |
| Urovant Sciences Inc | 1 | $124 |
| Neotract Inc. | 2 | $96 |
| Coloplast | 1 | $67 |
| Procept Biorobotics Corporation | 2 | $53 |
| Antares Pharma, Inc. | 1 | $50 |
| Myovant Sciences Inc. | 3 | $48 |
| Johnson & Johnson | 2 | $39 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$618
- AMS 700$278
- Xperience$270
- BlastX$270
- SurgX$270
- GEMTESA$249
- Axonics$134
- CVAC Aspiration System$128
- JELMYTO$120
- ESCAPE$118
- AMS 800 Artificial Urinary Sphincter$117
- AMS$111
- INTERSTIM ICON$107
How this compares
$11,706 in reported general payments places this provider in the 80th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 435 | $291,007 |
| MyrbetriqMirabegron | 47 | $40,318 |
| Estradiol | 454 | $33,921 |
| JatenzoTestosterone Undecanoate | 20 | $11,544 |
| PremarinEstrogens, Conjugated | 13 | $5,765 |
| Dutasteride | 116 | $3,832 |
| Tamsulosin Hcl | 196 | $3,122 |
| Bethanechol Chloride | 41 | $1,683 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,464 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $867 |
| Cephalexin | 63 | $776 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 75 | $668 |
| Finasteride | 66 | $641 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 29 | $567 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $223 | $291,007435 claims |
| Astellas Pharma US IncMyrbetriq | $296 | $40,31847 claims |
| PfizerPremarin | $15 | $5,76513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 878 urology providers in Texas.
Other urology in Edinburg
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jonathan Clavell HernandezHouston$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.